SRRK: Apitegromab nears FDA approval with strong data, global filings, and high launch readiness
Apitegromab is set for FDA review with strong phase III results in SMA, a robust manufacturing transition, and broad anticipated demand across age groups. Regulatory filings are advancing globally, and launch preparations include extensive patient and physician support.Based on Scholar Rock Holding…